Obesity and type 2 diabetes are increasingly being treated as problems that require only pharmaceutical solutions.
Instead of asking why metabolic disease has become so widespread, attention is turning towards drugs that suppress appetite, slow digestion and alter metabolism. The underlying food environment remains largely unchanged. People continue to be surrounded by sugar, refined carbohydrates and highly processed products, dietary guidelines remain unchallenged, and nutrition is missing from almost all educational curriculums.
This is the quick fix: medicate the physiology without seriously confronting what disrupted it.
A new study published in Nature Health should make this approach more difficult to accept without question.
Researchers used artificial intelligence to analyse more than 410,000 Reddit posts mentioning semaglutide or tirzepatide, the active ingredients in medications marketed under names including Ozempic, Wegovy, Mounjaro and Zepbound.
They identified 67,008 people who reported using these drugs. Of these, 43.5% described at least one side effect.
Nausea, vomiting, constipation and diarrhoea were prominent, as expected. But users also reported fatigue, menstrual irregularities, bleeding changes, chills, hot flushes and feeling unusually cold. These experiences may not be adequately reflected in clinical trials, product labels or conventional adverse-event reporting systems.
The study cannot prove that the drugs caused every reported symptom. Social-media data are self-reported, Reddit users do not represent the full population, and those experiencing problems may be more likely to post. However, these limitations should not obscure the central finding: tens of thousands of people are discussing unwanted experiences while using these medications, including possible safety signals that formal systems may have overlooked.
The pharmaceutical double standard
Known side effects have not prevented GLP-1 drugs from becoming an increasingly prominent response to obesity and type 2 diabetes. The possibility of additional, previously unrecognised effects is also unlikely to dislodge them from that position.
Pharmaceutical risks are treated as manageable trade-offs.
Low-carbohydrate, ketogenic and carnivore approaches are judged by a very different standard. They are routinely described as dangerous, extreme, or unsustainable, despite being food-based interventions that do not produce any pharmacological adverse effects. An LCHF approach removes or substantially reduces sugars and refined carbohydrates. It does not introduce a manufactured compound that pharmacologically suppresses appetite or slows the movement of food through the digestive system.
That distinction matters.
People taking insulin or blood-pressure medication may require careful monitoring when reducing carbohydrates. If glucose or blood pressure improves, an existing medication dose can become too strong. This is often presented as one of the dangers of the diet. In reality, it means that the medication no longer matches the person’s needs. The answer is not to continue eating the foods that contribute to elevated glucose so that the medication dose remains appropriate. The answer is to provide informed clinical support and review the medication safely.
The contradiction is difficult to ignore.
A drug may cause recognised side effects, generate new safety concerns, and still be accepted as a legitimate treatment. A nutritional intervention may improve glucose control and reduce medication requirements, yet remain excluded because it is considered too risky or difficult to sustain.
Medication is normalised.
Changing the food is treated as radical.
Avoiding the underlying question
The rise of GLP-1 medication reflects more than individual demand for an easier solution. It reflects a healthcare culture more comfortable prescribing treatment than questioning the nutritional conditions driving metabolic disease.
People are surrounded by highly processed foods, confusing advice, and constant marketing. They are told to eat less and move more, but are rarely given a clear explanation of insulin resistance, carbohydrate intolerance, or the effect of refined carbohydrates on glucose and hunger.
When generic advice fails, medication becomes the next step.
The possibility that changing the composition of the diet could be a central management tool is often dismissed before it is properly offered. Structural barriers unquestionably affect food choice. Income, geography, food prices and availability all matter. But recognising those barriers must not become an excuse to deny people practical knowledge or assume that communities are incapable of meaningful change.
Poverty limits choice. It does not erase agency.
What Eat Better South Africa (EBSA) demonstrates
Eat Better South Africa was created to put knowledge and agency back into metabolic healthcare. EBSA does not offer another product to manage the consequences of poor metabolic health. It helps participants understand what may be driving those consequences and what they can change. Participants learn how sugars and refined carbohydrates affect glucose and metabolic health. They identify hidden sugars, examine the foods available within their communities and make practical changes suited to their cultures and budgets.
Participants begin to connect what they eat with how they feel and what they measure. They become better able to interpret their results, recognise changes and engage with healthcare professionals.
They are not simply given a treatment. They are given the opportunity to understand and manage their health.
People deserve more than a pharmaceutical answer
The new study is important because it listened to what people were reporting after formal trials had ended and prescriptions had been written.
The same seriousness should be applied when people report improvements after changing their diet. Lower glucose, reduced hunger, improved energy and decreasing medication requirements should not be dismissed because the intervention does not come from a pharmaceutical company.
South Africa cannot medicate its way out of a metabolic-health crisis while leaving the conditions that created it untouched.
Greater access to drugs does not correct an unhealthy food environment. It does not teach people how their diet affects metabolic health. It does not build confidence, knowledge or self-management skills.
The response to obesity and type 2 diabetes must begin by confronting their underlying drivers. Therapeutic carbohydrate restriction should be available as a credible management option, supported by education, monitoring and appropriate clinical care.
The pharmaceutical answer may appear easier. But easier is not the same as better, and managing the consequence is not the same as addressing the cause.
Sehgal NKR, Tronieri JS, Ungar L, Guntuku SC. Self-reported side effects of semaglutide and tirzepatide in online communities. Nature Health. 2026;1(8):806.